Tuchman Lisa Kessler, Huppert Jill S, Huang Bin, Slap Gail B
Pediatric Residency Training Program, Cincinnati Children's Hospital Medical Center, Ohio, USA.
J Pediatr Adolesc Gynecol. 2005 Aug;18(4):255-60. doi: 10.1016/j.jpag.2005.05.004.
To compare weight and continuation among adolescents using monthly medroxyprogesterone acetate (MPA)/ethinyl estradiol cypionate (E2C), tri-monthly depot MPA (DMPA), and daily oral contraceptive pills (OCP).
Medical records were reviewed for body mass index, demographics, and sexual history at baseline; and weight and continuation at 3, 6, 9, and 12 months. Bivariate analyses were performed by method, and continuation functions were compared by the log-rank and Wilcoxon tests. The effect of method on use duration was assessed by Cox regression.
Hospital adolescent clinic.
12- to 21-year-old patients who initiated MPA/E2C, DMPA, or OCPs in 2001.
Weight gain and method continuation.
MPA/E2C was initiated by 40 (18%) patients, DMPA by 63 (28%), and OCPs by 119 (54%, P < 0.001). OCP users were younger (P = 0.005) and more likely to be white, privately insured, and in school (P < 0.004) than MPA/E2C or DMPA users. Previous DMPA and OCP use, pregnancy, and sexually transmitted infections (STI) were more common among MPA/E2C than DMPA or OCP users (P < or = 0.001). Baseline BMI was lowest (P = 0.06) among DMPA users, and MPA/E2C users were most likely to be overweight (P = 0.03). There were non-significant differences in weight change. Continuation functions differed by the method only in the first three months of use (P = 0.03). Leading reasons for discontinuation were unavailability of MPA/E2C (20%), bleeding with DMPA (22%), and forgetting OCPs (17%). Duration of use was independently associated with white race (P < 0.005) and STI-never (P < 0.0001) but not with method type.
Although MPA/E2C use was associated with overweight status and early discontinuation, it also was associated with previous use of other methods. For all methods, poor continuation at one year supports the ongoing search for effective contraceptive alternatives.
比较使用每月注射醋酸甲羟孕酮(MPA)/环戊丙酸炔雌醇(E2C)、每三个月注射一次长效醋酸甲羟孕酮(DMPA)和每日口服避孕药(OCP)的青少年的体重及持续使用情况。
回顾医疗记录,获取基线时的体重指数、人口统计学资料及性病史;以及3、6、9和12个月时的体重和持续使用情况。按方法进行双变量分析,并通过对数秩检验和威尔科克森检验比较持续使用函数。通过Cox回归评估方法对使用持续时间的影响。
医院青少年诊所。
2001年开始使用MPA/E2C、DMPA或OCP的12至21岁患者。
体重增加和方法持续使用情况。
40名(18%)患者开始使用MPA/E2C,63名(28%)患者开始使用DMPA,119名(54%)患者开始使用OCP(P<0.001)。与使用MPA/E2C或DMPA的患者相比,使用OCP的患者更年轻(P = 0.005),更可能是白人、有私人保险且在校(P<0.004)。与使用DMPA或OCP的患者相比,使用MPA/E2C的患者中,既往使用DMPA和OCP、怀孕及性传播感染(STI)更为常见(P≤0.001)。DMPA使用者的基线体重指数最低(P = 0.06),而MPA/E2C使用者超重的可能性最大(P = 0.03)。体重变化无显著差异。持续使用函数仅在使用的前三个月因方法不同而有差异(P = 0.03)。停药的主要原因是无法获得MPA/E2C(20%)、DMPA出血(22%)和忘记服用OCP(17%)。使用持续时间与白人种族(P<0.005)和从未感染性传播感染(P<0.0001)独立相关,但与方法类型无关。
尽管使用MPA/E2C与超重状态和早期停药有关,但也与既往使用其他方法有关。对于所有方法,一年时的持续使用情况不佳支持继续寻找有效的避孕替代方法。